中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 41 Issue 3
Mar.  2025
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(3): 409-414

The application of human serum albumin in liver cirrhosis and its complications

DOI: 10.12449/JCH250303

  • Department of Hepatology and Gastroenterology，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

Research funding:

Capital Medical Development and Research Fund (2022-1-2181)

More Information
  • Corresponding author: DING Huiguo， dinghuiguo@ccmu.edu.cn （ORCID： 0000-0002-8716-4926）
  • Received Date: 2024-10-08
  • Accepted Date: 2025-01-15
  • Published Date: 2025-03-25
    Abstract
  • Albumin is synthesized in the liver， and in case of severe liver injury， albumin synthesis is reduced with structural alterations （such as an increase in methylation and glycosylation）， leading to a significant reduction in effective albumin in circulation. Albumin not only maintains plasma oncotic pressure， but also has the functions of antioxidation， anti-inflammation， immunomodulation， and transport. Current guidelines recommend the short-term application of human serum albumin in the treatment of large-volume paracentesis， hepatorenal syndrome， and spontaneous bacterial peritonitis in patients with liver cirrhosis， as it is shown that human serum albumin can help to reduce mortality. In addition， human serum albumin may improve the prognosis of cirrhotic patients with hyponatremia， non-SBP infections， and hepatic encephalopathy. However， there are still controversies over the application of human serum albumin in liver cirrhosis and related complications in terms of optimal dose and long-term efficacy.

     

    • FullText(HTML)
    • References(51)
  • [1]
    GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/s0140-6736(21)01374-x.
    [2]
    de MATTOS ÂZ, SIMONETTO DA, TERRA C, et al. Albumin administration in patients with cirrhosis: Current role and novel perspectives[J]. World J Gastroenterol, 2022, 28( 33): 4773- 4786. DOI: 10.3748/wjg.v28.i33.4773.
    [3]
    POMPILI E, ZACCHERINI G, BALDASSARRE M, et al. Albumin administration in internal medicine: A journey between effectiveness and futility[J]. Eur J Intern Med, 2023, 117: 28- 37. DOI: 10.1016/j.ejim.2023.07.003.
    [4]
    BAI ZH, MÉNDEZ-SÁNCHEZ N, ROMEIRO FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement[J]. JHEP Rep, 2023, 5( 8): 100785. DOI: 10.1016/j.jhepr.2023.100785.
    [5]
    ANDERSEN JT, DALHUS B, VIUFF D, et al. Extending serum half-life of albumin by engineering neonatal Fc receptor(FcRn) binding[J]. J Biol Chem, 2014, 289( 19): 13492- 13502. DOI: 10.1074/jbc.M114.549832.
    [6]
    WU NJ, LIU TT, TIAN MM, et al. Albumin, an interesting and functionally diverse protein, varies from‘native’ to‘effective’(Review)[J]. Mol Med Rep, 2024, 29( 2): 24. DOI: 10.3892/mmr.2023.13147.
    [7]
    GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58( 5): 1836- 1846. DOI: 10.1002/hep.26338.
    [8]
    CASULLERAS M, FLORES-COSTA R, DURAN-GÜELL M, et al. Albumin lipidomics reveals meaningful compositional changes in advanced cirrhosis and its potential to promote inflammation resolution[J]. Hepatol Commun, 2022, 6( 6): 1443- 1456. DOI: 10.1002/hep4.1893.
    [9]
    CASULLERAS M, FLORES-COSTA R, DURAN-GÜELL M, et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis[J]. Sci Transl Med, 2020, 12( 566): eaax5135. DOI: 10.1126/scitranslmed.aax5135.
    [10]
    BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: New concepts and perspectives[J]. Gut, 2020, 69( 6): 1127- 1138. DOI: 10.1136/gutjnl-2019-318843.
    [11]
    AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70( 1): 9- 29. DOI: 10.1136/gutjnl-2020-321790.
    [12]
    SIMONETTI RG, PERRICONE G, NIKOLOVA D, et al. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis[J]. Cochrane Database Syst Rev, 2019, 6( 6): CD004039. DOI: 10.1002/14651858.CD004039.pub2.
    [13]
    SHRESTHA DB, BUDHATHOKI P, SEDHAI YR, et al. Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: A systematic review and meta-analysis[J]. Ann Hepatol, 2021, 26: 100547. DOI: 10.1016/j.aohep.2021.100547.
    [14]
    BAI ZH, WANG L, WANG R, et al. Use of human albumin infusion in cirrhotic patients: A systematic review and meta-analysis of randomized controlled trials[J]. Hepatol Int, 2022, 16( 6): 1468- 1483. DOI: 10.1007/s12072-022-10374-z.
    [15]
    XU XY, DING HG, JIA JD, et al. Chinese guidelines on the management of ascites in cirrhosis: Chinese Society of Hepatology, Chinese Medical Association[J]. Hepatol Int, 2024, 18( 4): 1071- 1089. DOI: 10.1007/s12072-024-10697-z.
    [16]
    ALESSANDRIA C, ELIA C, MEZZABOTTA L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study[J]. Dig Liver Dis, 2011, 43( 11): 881- 886. DOI: 10.1016/j.dld.2011.06.001.
    [17]
    CHINA L, FREEMANTLE N, FORREST E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis[J]. N Engl J Med, 2021, 384( 9): 808- 817. DOI: 10.1056/NEJMoa2022166.
    [18]
    ARORA V, VIJAYARAGHAVAN R, MAIWALL R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure[J]. Hepatology, 2020, 72( 3): 1043- 1055. DOI: 10.1002/hep.31071.
    [19]
    TORP N, ISRAELSEN M, COENRAAD M, et al. Personalised human albumin in patients with cirrhosis and ascites: Design and rationale for the ALB-TRIAL—a randomised clinical biomarker validation trial[J]. BMJ Open, 2024, 14( 2): e079309. DOI: 10.1136/bmjopen-2023-079309.
    [20]
    MATTOS AA, WILTGEN D, JOTZ RF, et al. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis[J]. Ann Hepatol, 2020, 19( 5): 451- 457. DOI: 10.1016/j.aohep.2020.04.010.
    [21]
    PAINE CH, BIGGINS SW, PICHLER RH. Albumin in cirrhosis: More than a colloid[J]. Curr Treat Options Gastroenterol, 2019, 17( 2): 231- 243. DOI: 10.1007/s11938-019-00227-4.
    [22]
    SORT P, NAVASA M, ARROYO V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. N Engl J Med, 1999, 341( 6): 403- 409. DOI: 10.1056/NEJM199908053410603.
    [23]
    KAR PS, VENISHETTY S, LAROIA ST, et al. Tolerance of standard dose albumin infused over 6 hrs for treatment of spontaneous bacterial peritonitis-a randomized controlled trial[J]. Indian J Gastroenterol, 2023, 42( 4): 505- 516. DOI: 10.1007/s12664-023-01389-x.
    [24]
    GARCIA-TSAO G, ABRALDES JG, RICH NE, et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review[J]. Gastroenterology, 2024, 166( 1): 202- 210. DOI: 10.1053/j.gastro.2023.10.016.
    [25]
    NADIM MK, KELLUM JA, FORNI L, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative(ADQI) and International Club of Ascites(ICA) joint multidisciplinary consensus meeting[J]. J Hepatol, 2024, 81( 1): 163- 183. DOI: 10.1016/j.jhep.2024.03.031.
    [26]
    ORTEGA R, GINÈS P, URIZ J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study[J]. Hepatology, 2002, 36( 4 Pt 1): 941- 948. DOI: 10.1053/jhep.2002.35819.
    [27]
    BAI ZH, GUO XZ, TACKE F, et al. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819881302. DOI: 10.1177/1756284819881302.
    [28]
    IS B, BOMBASSARO IZ, TOVO CV, et al. Albumin in the management of hepatic encephalopathy: A systematic review and meta-analysis[J]. Ann Hepatol, 2021, 26: 100541. DOI: 10.1016/j.aohep.2021.100541.
    [29]
    TEH KB, LOO JH, TAM YC, et al. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis[J]. Dig Liver Dis, 2021, 53( 7): 817- 823. DOI: 10.1016/j.dld.2021.04.030.
    [30]
    SHARMA BC, SINGH J, SRIVASTAVA S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy[J]. J Gastroenterol Hepatol, 2017, 32( 6): 1234- 1239. DOI: 10.1111/jgh.13666.
    [31]
    FAGAN A, GAVIS EA, GALLAGHER ML, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study[J]. J Hepatol, 2023, 78( 2): 312- 321. DOI: 10.1016/j.jhep.2022.09.009.
    [32]
    BAJAJ JS, TANDON P, O’LEARY JG, et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis[J]. Am J Gastroenterol, 2018, 113( 9): 1339. DOI: 10.1038/s41395-018-0119-3.
    [33]
    BAI ZH, XU WT, CHAI L, et al. Effects of short-term human albumin infusion for the prevention and treatment of hyponatremia in patients with liver cirrhosis[J]. J Clin Med, 2022, 12( 1): 107. DOI: 10.3390/jcm12010107.
    [34]
    CHINA L, FREEMANTLE N, FORREST E, et al. Targeted albumin therapy does not improve short-term outcome in hyponatremic patients hospitalized with complications of cirrhosis: Data from the ATTIRE trial[J]. Am J Gastroenterol, 2021, 116( 11): 2292- 2295. DOI: 10.14309/ajg.0000000000001488.
    [35]
    FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157( 1): 149- 162. DOI: 10.1053/j.gastro.2019.03.021.
    [36]
    FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2020, 18( 4): 963- 973. e 14. DOI: 10.1016/j.cgh.2019.07.055.
    [37]
    WONG YJ, QIU TY, TAM YC, et al. Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis[J]. Dig Liver Dis, 2020, 52( 10): 1137- 1142. DOI: 10.1016/j.dld.2020.05.047.
    [38]
    MAIWALL R, KUMAR A, PASUPULETI SSR, et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension[ALPS trial][J]. J Hepatol, 2022, 77( 3): 670- 682. DOI: 10.1016/j.jhep.2022.03.043.
    [39]
    CALLUM J, SKUBAS NJ, BATHLA A, et al. Use of intravenous albumin: A guideline from the international collaboration for transfusion medicine guidelines[J]. Chest, 2024, 166( 2): 321- 338. DOI: 10.1016/j.chest.2024.02.049.
    [40]
    DI PASCOLI M, FASOLATO S, PIANO S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites[J]. Liver Int, 2019, 39( 1): 98- 105. DOI: 10.1111/liv.13968.
    [41]
    CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
    [42]
    WIEDERMANN CJ. Controversies surrounding albumin use in sepsis: Lessons from cirrhosis[J]. Int J Mol Sci, 2023, 24( 24): 17606. DOI: 10.3390/ijms242417606.
    [43]
    CAIRONI P, TOGNONI G, MASSON S, et al. Albumin replacement in patients with severe sepsis or septic shock[J]. N Engl J Med, 2014, 370( 15): 1412- 1421. DOI: 10.1056/NEJMoa1305727.
    [44]
    FINFER S, BELLOMO R, BOYCE N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit[J]. N Engl J Med, 2004, 350( 22): 2247- 2256. DOI: 10.1056/NEJMoa040232.
    [45]
    CHARPENTIER J, MIRA JP. Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: The EARSS study[J]. Intensive Care Med, 2011, 37: S115.
    [46]
    PHILIPS CA, MAIWALL R, SHARMA MK, et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis(FRISC study): A randomized controlled trial[J]. Hepatol Int, 2021, 15( 4): 983- 994. DOI: 10.1007/s12072-021-10164-z.
    [47]
    PARK CHL, DE ALMEIDA JP, DE OLIVEIRA GQ, et al. Lactated Ringer’s versus 4% albumin on lactated Ringer’s in early sepsis therapy in cancer patients: A pilot single-center randomized trial[J]. Crit Care Med, 2019, 47( 10): e798- e805. DOI: 10.1097/CCM.0000000000003900.
    [48]
    GENG L, TIAN XX, GAO ZF, et al. Different concentrations of albumin versus crystalloid in patients with sepsis and septic shock: A meta-analysis of randomized clinical trials[J]. J Intensive Care Med, 2023, 38( 8): 679- 689. DOI: 10.1177/08850666231170778.
    [49]
    SHASTHRY SM, KUMAR M, KHUMUCKHAM JS, et al. Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion[J]. Liver Int, 2017, 37( 8): 1167- 1176. DOI: 10.1111/liv.13375.
    [50]
    JAGDISH RK, MARAS JS, SARIN SK. Albumin in advanced liver diseases: The good and bad of a drug![J]. Hepatology, 2021, 74( 5): 2848- 2862. DOI: 10.1002/hep.31836.
    [51]
    FORSTER CM, HALLS S, ALLARAKHIA S, et al. Improving appropriate use of intravenous albumin: Results of a single-centre audit and multifaceted intervention[J]. BMJ Open Qual, 2024, 13( 2): e002534. DOI: 10.1136/bmjoq-2023-002534.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1538) PDF downloads(65) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2713]YesterdayPV[4302]TodayIP[480]TodayPV[794]Online[117]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return